Novartis Ag (NVS) Gross Profit Margin starting from the fourth quarter 2025 to fourth quarter 2024, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Novartis Ag  (NYSE: NVS)


Novartis Ag's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NVS Gross Profit Margin (Dec 31 2025)
Q4 		0
Q3 		0
Q2 		0
Q1 		(Dec 31 2024)
Q4
Y / Y Revenue Change 9.57 %
Seq. Revenue Change -
Revenue In Millions $56,674.00
Gross Profit Margin 75.83 %
Gross Profit Margin Total Ranking # 872
Gross Profit In Millions $42,975.00
Y / Y Gross Profit Change 10.49 %
Seq. Gross Profit Change -


Commenting fourth quarter 2025 Gross Profit Margin



Observing fourth quarter 2025 results within Major Pharmaceutical Preparations industry 79 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from to 872.
Learn about Gross Margin
NVS's Gross Profit Margin fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 80
Healthcare Sector # 152
Overall # 863

Gross Profit Margin Statistics
High Average Low
75.83 % 71.23 % 65.38 %
(Dec 31 2025)   (Dec 31 2018)


NVS Gross Income Trends • More of NVS's Profitabilty Ratios • NVS Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
NVS's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
NVS's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for NVS's Competitors
Gross Profit Margin Profit Margin for Novartis Ag's Suppliers
Gross Profit Margin Profit Margin for NVS's Customers

You may also want to know
NVS's Annual Growth Rates NVS's Profitability Ratios NVS's Asset Turnover Ratio NVS's Dividend Growth
NVS's Roe NVS's Valuation Ratios NVS's Financial Strength Ratios NVS's Gross Profit Growth
NVS's Roa NVS's Inventory Turnover Ratio NVS's Growth Rates NVS's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Gross Profit MarginDec 31 2025 MRQ Gross ProfitDec 31 2025 MRQ Revenue
Zai Lab Limited  99.98 %$ 127.567  Millions$ 127.597  Millions
Ptc Therapeutics inc   99.76 %$ 164.277  Millions$ 164.677  Millions
Corcept Therapeutics Inc  98.74 %$ 199.580  Millions$ 202.125  Millions
Verastem Inc   98.40 %$ 17.255  Millions$ 17.535  Millions
Travere Therapeutics Inc   98.03 %$ 127.134  Millions$ 129.688  Millions
Ovid Therapeutics Inc   97.77 %$ 0.702  Millions$ 0.718  Millions
Galapagos Nv  97.33 %$ 1,212.413  Millions$ 1,245.718  Millions
Lexicon Pharmaceuticals Inc   96.34 %$ 5.292  Millions$ 5.493  Millions
Karyopharm Therapeutics Inc   95.65 %$ 32.595  Millions$ 34.079  Millions
Zevra Therapeutics Inc   95.55 %$ 32.605  Millions$ 34.125  Millions
Gyre Therapeutics Inc   95.31 %$ 35.452  Millions$ 37.195  Millions
Liquidia Corporation  94.78 %$ 87.214  Millions$ 92.021  Millions
Bridgebio Pharma Inc   94.74 %$ 146.071  Millions$ 154.178  Millions
Rafael Holdings Inc  94.31 %$ 0.199  Millions$ 0.211  Millions
Emmaus Life Sciences Inc   93.90 %$ 3.617  Millions$ 3.852  Millions
Axsome Therapeutics Inc   93.71 %$ 183.670  Millions$ 195.999  Millions
Genmab A  93.60 %$ 3,482.000  Millions$ 3,720.000  Millions
Vanda Pharmaceuticals Inc   93.30 %$ 53.383  Millions$ 57.216  Millions
Uniqure N v   92.19 %$ 5.133  Millions$ 5.568  Millions
Regeneron Pharmaceuticals Inc   91.80 %$ 3,565.600  Millions$ 3,884.300  Millions
Rhythm Pharmaceuticals Inc   91.61 %$ 52.451  Millions$ 57.253  Millions
Rigel Pharmaceuticals Inc  91.47 %$ 63.847  Millions$ 69.802  Millions
Ardelyx inc   91.34 %$ 114.366  Millions$ 125.215  Millions
Urogen Pharma Ltd   91.31 %$ 34.548  Millions$ 37.837  Millions
Arcutis Biotherapeutics Inc   90.97 %$ 117.815  Millions$ 129.503  Millions
Acadia Pharmaceuticals Inc   90.77 %$ 257.764  Millions$ 283.989  Millions
Agios Pharmaceuticals Inc   90.59 %$ 18.088  Millions$ 19.967  Millions
Beone Medicines Ltd   90.49 %$ 1,355.748  Millions$ 1,498.170  Millions
Ascendis Pharma A  90.29 %$ 251.914  Millions$ 278.993  Millions
Kiniksa Pharmaceuticals International Plc  89.64 %$ 181.182  Millions$ 202.127  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.